Full-Time

Key Account Leader

Posted on 1/5/2026

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$131.3k - $192.5k/yr

+ Bonus + Equity

Cleveland, OH, USA + 3 more

More locations: Pittsburgh, PA, USA | Columbus, OH, USA | Cincinnati, OH, USA

Hybrid

40–60% travel within geography; field-based role, travel to HQ Irvine, CA as needed

Category
Sales & Account Management (1)
Required Skills
Data Analysis
Requirements
  • Geography requirement: Candidate must live in Columbus, Cleveland, Cincinnati, or Pittsburgh
  • Bachelor’s degree in business, science, or related field or commensurate experience
  • At least 8 years of professional experience in pharmaceutical sales, account management, market access or relevant healthcare experience, with a minimum of 4+ years direct pharmaceutical sales experience
  • Established track record of managing complex or strategic accounts with evidence of excellent problem-solving and collaboration
  • Highly adaptable to change, able to quickly pivot and respond given new market information in a fast-paced environment
  • Strong communication, teamwork and change management skills
  • Proven ability to make tough decisions and escalate appropriate issues
  • 40 – 60%+ travel may be required within the geography and additional travel to HQ in Irvine, CA
  • This is a field-based position reporting to the District Sales Leader
  • Eye Care experience and successful launch experience (strongly preferred)
Responsibilities
  • Deliver sales results across a defined strategic target list and geography through compliant, high-impact sales engagement to exceed sales goals
  • Lead with strong business acumen, utilizing advanced analytics, insights, and field intelligence to identify growth opportunities and performance drivers
  • Develop and execute strategic and tactical account plans that translate data into clear, outcome-driven action
  • Understand stakeholder priorities within key accounts and tailor engagement to accelerate adoption and utilization
  • Execute a disciplined call strategy that deepens relationships, expands product experience, and drives impactful information exchange
  • Leverage market access opportunities to expand reach and improve patient pathways
  • Prioritize and manage a diverse portfolio of strategic accounts with clarity and focus
  • Share ongoing insights with leadership and internal stakeholders to ensure feedback is captured
  • Set the standard of outstanding compliant teamwork and collaboration with partner territory leaders, the district leader, sales leadership, medical team members, field reimbursement managers, sales ops, training, marketing and market access, to maximize sales performance
  • Drive the Tarsus culture of commitment, empowerment and teamwork including extreme ownership, inclusion, high accountability, continuous improvement, relentless pursuit of excellence and FUN
  • Achieve success and be prepared to adapt in a complex selling environment
  • Ensure PDMA compliance and adhere to all company & industry compliance guidelines
  • Share ongoing best practices among peers and leadership to elevate national performance
  • Connect territory opportunities and strategic customers to sales leadership and senior Tarsus leadership – driving the culture of customer connectivity
  • Bring a deep, holistic understanding of the eye care ecosystem, with fluency in anterior segment disease and how eye care professionals make decisions for total patient care
  • Develop expert level knowledge of ocular surface disease (OSD) and lid health—diagnostics, treatment modalities (OTC, therapeutic, procedural), and real-world practice behavior
  • Navigate the full practice workflow and understand how each stakeholder—from technicians to prescribers — contribute to patient care
  • Identify gaps and elevate patient care by aligning clinical insights with practice needs
  • Integrate market access considerations into all strategic recommendations
  • Build credible relationships with key opinion leaders and influencers; effectively connect them to Tarsus leadership
  • Serve as a trusted, compliant clinical and product expert who enhances the reputation of Tarsus across the eye care community
Desired Qualifications
  • Eye Care experience and successful launch experience is strongly preferred
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tarsus Pharamceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

5%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

INACTIVE